Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34518623/
Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited....
-
KRAS Oncogene Connect4yrKey Points • Conclusion/Relevance: “This study reports a significant survival benefit of ICIs over chemotherapy or local control alone in patients with NSCLCBM [NSCLC brain metastases]. This retrospective analysis of patients treated Show More
Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34518295/
KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic...
Targeting mutated GTPase KRAS in tumor therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34520956/
Kirsten rat sarcoma virus oncogene (KRAS) mutation accounts for approximately 85% of RAS-driven cancers, and participates in multiple signaling pathways and mediates cell proliferation, differentiation and metabolism. KRAS has been...
Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34481168/
Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mutations in circulating tumor DNA (ctDNA). In this prospective study, the clinical value of...
-
KRAS Oncogene Connect4yrKey Points • Conclusion/Relevance: “Together, this is the first study showing that ctDNA analysis on supernatant PE could be used for therapy response monitoring. Due to a higher ctDNA concentration and fractional Show More
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34503301/
Broad-spectrum therapeutics in non-small cell lung cancer (NSCLC) are in demand. Most human solid tumors express proteoglycans modified with distinct oncofetal chondroitin sulfate (CS) chains that can be detected and...